文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在治疗的前 10 天内实现了皮肤利什曼病愈合分子特征的巩固。

Consolidation of a Molecular Signature of Healing in Cutaneous Leishmaniasis Is Achieved during the First 10 Days of Treatment.

机构信息

Centro Internacional de Entrenamiento e Investigaciones Médicas, Cali, Colombia.

Universidad Icesi, Cali, Colombia.

出版信息

J Immunol. 2024 Mar 1;212(5):894-903. doi: 10.4049/jimmunol.2300576.


DOI:10.4049/jimmunol.2300576
PMID:38231122
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10922383/
Abstract

The immune response is central to the pathogenesis of cutaneous leishmaniasis (CL). However, most of our current understanding of the immune response in human CL derives from the analysis of systemic responses, which only partially reflect what occurs in the skin. In this study, we characterized the transcriptional dynamics of skin lesions during the course of treatment of CL patients and identified gene signatures and pathways associated with healing and nonhealing responses. We performed a comparative transcriptome profiling of serial skin lesion biopsies obtained before, in the middle, and at the end of treatment of CL patients (eight who were cured and eight with treatment failure). Lesion transcriptomes from patients who healed revealed recovery of the stratum corneum, suppression of the T cell-mediated inflammatory response, and damping of neutrophil activation, as early as 10 d after initiation of treatment. These transcriptional programs of healing were consolidated before lesion re-epithelization. In stark contrast, downregulation of genes involved in keratinization was observed throughout treatment in patients who did not heal, indicating that in addition to uncontrolled inflammation, treatment failure of CL is mediated by impaired mechanisms of wound healing. This work provides insights into the factors that contribute to the effective resolution of skin lesions caused by Leishmania (Viannia) species, sheds light on the consolidation of transcriptional programs of healing and nonhealing responses before the clinically apparent resolution of skin lesions, and identifies inflammatory and wound healing targets for host-directed therapies for CL.

摘要

免疫反应是皮肤利什曼病(CL)发病机制的核心。然而,我们目前对人类 CL 中免疫反应的大部分了解都来自于对全身反应的分析,而全身反应仅部分反映了皮肤中发生的情况。在这项研究中,我们对 CL 患者治疗过程中的皮肤病变进行了转录动力学特征分析,并确定了与愈合和非愈合反应相关的基因特征和途径。我们对接受治疗的 CL 患者的连续皮肤病变活检进行了比较转录组分析(治愈的 8 例和治疗失败的 8 例)。在治疗开始后 10 天,愈合患者的病变转录组显示出角质层恢复、T 细胞介导的炎症反应抑制和中性粒细胞激活减弱,这表明愈合的转录程序早在病变再上皮化之前就已得到巩固。与此形成鲜明对比的是,在未愈合的患者中,参与角化的基因下调贯穿整个治疗过程,这表明除了不受控制的炎症外,CL 的治疗失败还受到伤口愈合机制受损的介导。这项工作深入了解了有助于有效解决利什曼(Viannia)物种引起的皮肤病变的因素,阐明了在皮肤病变临床明显消退之前愈合和非愈合反应的转录程序的巩固,并确定了针对 CL 的宿主导向治疗的炎症和伤口愈合靶点。

相似文献

[1]
Consolidation of a Molecular Signature of Healing in Cutaneous Leishmaniasis Is Achieved during the First 10 Days of Treatment.

J Immunol. 2024-3-1

[2]
Interventions for Old World cutaneous leishmaniasis.

Cochrane Database Syst Rev. 2017-12-1

[3]
Interventions for Old World cutaneous leishmaniasis.

Cochrane Database Syst Rev. 2017-11-17

[4]
Systematic suppression of Leishmania (Leishmania) amazonensis-mediated delayed-type hypersensitivity response in American cutaneous leishmaniasis.

Parasit Vectors. 2025-8-5

[5]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[6]
Modulation of fibroblast behavior by Leishmania: a pathway to understanding disease progression in cutaneous leishmaniasis.

BMC Microbiol. 2025-8-11

[7]
Antibiotics and antiseptics for surgical wounds healing by secondary intention.

Cochrane Database Syst Rev. 2016-3-29

[8]
Extracellular Vesicle Release from Immune Cells in Cutaneous Leishmaniasis: Modulation by and Reversal by Antimonial Therapy.

Pathogens. 2025-8-4

[9]
Senescence-related genes are associated with the immunopathology signature of American tegumentary leishmaniasis lesions and may predict progression to mucosal leishmaniasis.

Clin Exp Immunol. 2025-1-21

[10]
Efficacy of meglumine antimoniate treatment on boxer skin lesions: case report.

Front Vet Sci. 2025-6-30

引用本文的文献

[1]
Innate biosignature of treatment failure in human cutaneous leishmaniasis.

Nat Commun. 2025-4-4

本文引用的文献

[1]
Quality parameters for RNA preparations from biopsies of ulcerated human skin.

Wellcome Open Res. 2023-2-28

[2]
Graphia: A platform for the graph-based visualisation and analysis of high dimensional data.

PLoS Comput Biol. 2022-7

[3]
The reactome pathway knowledgebase 2022.

Nucleic Acids Res. 2022-1-7

[4]
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.

PLoS Negl Trop Dis. 2020-2-28

[5]
Profiles of Local and Systemic Inflammation in the Outcome of Treatment of Human Cutaneous Leishmaniasis Caused by ().

Infect Immun. 2020-2-20

[6]
Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis.

Sci Transl Med. 2019-11-20

[7]
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype.

Nat Biotechnol. 2019-8-2

[8]
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.

PLoS Negl Trop Dis. 2017-4-5

[9]
Salmon provides fast and bias-aware quantification of transcript expression.

Nat Methods. 2017-3-6

[10]
Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.

Antimicrob Agents Chemother. 2017-2-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索